Since Dan O'Connor stepped in as CEO at Ambrx, its stock has rallied on the revival of a previously shelved anti-HER2 ADC. It also raised $78 million and completed its ATM offering. A former marine captain, O'Connor’s leadership is anything but militaristic, though his time served helped shape his style and approach to adverse conditions. On the Business of Biotech, we welcome Dan back to discuss the resurgence of Ambrx.
In ISR’s Clinical Manufacturing Market Outlook report, we asked sponsors about their top reasons for being satisfied with an outsourced clinical trial manufacturing project.
Biopharma’s willingness to take big risks is evident in the dermatology therapeutic area, even as executives must continue managing through a shaky financial environment.
Notwithstanding the continuation of the macroeconomic and geopolitical headwinds faced in 2022 into 2023, many market observers remain optimistic that biotech M&A activity will rebound.
The successful use of artificial intelligence (AI) has been a long time coming. Today, more than 530 AI/ML-enabled medical devices have been authorized by the FDA. This article highlights some promising examples.
This biopharmaceutical company had to overcome trial master file (TMF) transfer from a previous licensee, staff turnover, and then a resubmission of its NDA.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
